GU Cancers 2022 | The U.S. Physician PARADIGM Study

Shilpa Gupta, MD, University of Minnesota, Minneapolis, MN, talks on the U.S. Physician PARADIGM study, which looked at trends in the physician prescriptions of front-line systemic therapy for patients with metastatic urothelial carcinoma. The study involved a targeted literature search (between January 2018 and March 2021) and qualitative interviews of urologists and medical oncologists in the USA. An estimated 75% of patients of interviewed physicians were receiving systemic therapy, with the most popular choice of systemic therapy being platinum-based chemotherapy followed by avelumab maintenance therapy. Single agent immunotherapy was used for patients who were ineligible for or who chose not to undergo platinum-based chemotherapy. The interviews revealed that the uptake of systemic therapies appears to be higher in reality than is suggested in the literature. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.